The efficacy and safety of 0.01% atropine alone or combined with orthokeratology for children with myopia: A meta-analysis
To evaluate the efficacy and safety of 0.01% atropine alone and in combination with orthokeratology for myopia control using a meta-analysis. PubMed, Cochrane Library, and EMBASE were searched. We included eligible randomized controlled trials (RCTs), non-RCTs, and retrospective cohort studies, publ...
Gespeichert in:
| Veröffentlicht in: | PloS one 2023-07, Vol.18 (7), p.e0282286-e0282286 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0282286 |
|---|---|
| container_issue | 7 |
| container_start_page | e0282286 |
| container_title | PloS one |
| container_volume | 18 |
| creator | Wang, Zengying Wang, Pengfei Jiang, Bohua Meng, Yifei Qie, Sufang Yan, Zhipeng |
| description | To evaluate the efficacy and safety of 0.01% atropine alone and in combination with orthokeratology for myopia control using a meta-analysis.
PubMed, Cochrane Library, and EMBASE were searched. We included eligible randomized controlled trials (RCTs), non-RCTs, and retrospective cohort studies, published up to August 1, 2022. We calculated the weighted mean difference (WMD) and 95% confidence interval (CI) for all outcomes and plotted them in forest plots.
Fourteen studies were included; 4 and 11 in the 0.01% atropine monotherapy and atropine-orthokeratology (AOK) groups, respectively. Compared with orthokeratology (OK) alone, 0.01% atropine alone had similar effects on slowing the axial elongation (WMD: -0.00 mm; 95% CI: -0.05-0.04, p |
| doi_str_mv | 10.1371/journal.pone.0282286 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2842436695</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A758522938</galeid><sourcerecordid>A758522938</sourcerecordid><originalsourceid>FETCH-LOGICAL-c627t-abbc4298ce487d181a5c6d00fecbad534d8bb33792aabacceeb96fb190ba1e9a3</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhiMEoqXwDxBYQiA4bHDsfHJBq4qPSpUqQeFqTZzxxsWJl9gBwq_HYdNqF_WAfLA1fuZ9RzMTRY8TGie8SF5f2XHowcRb22NMWclYmd-JjpOKs1XOKL-79z6KHjh3RWnGyzy_Hx3xIq1SntPj6PdliwSV0hLkRKBviAOFfiJWERrT5DkBP9it7pGACU7EDkTarg6BhvzUvg0B39pvOIC3xm4momai1aYZsN8R3RQE4A1Zkw49rCBUPTntHkb3FBiHj5b7JPry_t3l6cfV-cWHs9P1-UrmrPArqGuZsqqUmJZFk5QJZDJvKFUoa2gynjZlXXNeVAygBikR6ypXdVLRGhKsgJ9ET3e6W2OdWNrmBCtTFnqQV1kg3i7EWHfYSOz9AEZsB93BMAkLWhz-9LoVG_tDJJQXtKBlUHi5KAz2-4jOi047icZAj3b8a8ZnNq8C-uwf9PaSFmoDBoXulQ3GchYV6yIrM8YqPtvGt1DhNNhpGcaldIgfJLw6SAiMx19-A6Nz4uzzp_9nL74esi_22BbB-NZZM3pte3cIpjtQDta5AdVNlxMq5r2-7oaY91osex3SnuxP6CbpepH5HzAx9Nc</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2842436695</pqid></control><display><type>article</type><title>The efficacy and safety of 0.01% atropine alone or combined with orthokeratology for children with myopia: A meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Wang, Zengying ; Wang, Pengfei ; Jiang, Bohua ; Meng, Yifei ; Qie, Sufang ; Yan, Zhipeng</creator><contributor>Li, Wei</contributor><creatorcontrib>Wang, Zengying ; Wang, Pengfei ; Jiang, Bohua ; Meng, Yifei ; Qie, Sufang ; Yan, Zhipeng ; Li, Wei</creatorcontrib><description>To evaluate the efficacy and safety of 0.01% atropine alone and in combination with orthokeratology for myopia control using a meta-analysis.
PubMed, Cochrane Library, and EMBASE were searched. We included eligible randomized controlled trials (RCTs), non-RCTs, and retrospective cohort studies, published up to August 1, 2022. We calculated the weighted mean difference (WMD) and 95% confidence interval (CI) for all outcomes and plotted them in forest plots.
Fourteen studies were included; 4 and 11 in the 0.01% atropine monotherapy and atropine-orthokeratology (AOK) groups, respectively. Compared with orthokeratology (OK) alone, 0.01% atropine alone had similar effects on slowing the axial elongation (WMD: -0.00 mm; 95% CI: -0.05-0.04, p<0.31), while AOK significantly lowered axial growth. Moreover, the baseline myopic degree and duration of treatment were influential for the change in axial elongation (WMD: -0.12 mm; 95% CI: -0.17--0.07, p = 0.00001 and WMD: -0.11 mm; 95% CI: -0.15--0.108, p<0.00001, respectively). Additionally, the AOK may reduce the change rate of the spherical equivalent refraction and the accommodation amplitude (WMD: -0.13 D; 95% CI: 0.07-0.19, p<0.001 and WMD: -1.08 mm; 95% CI: -1.73--0.43, p<0.0001, respectively), and cause a slight increase in the diameter of the pupil (WMD: 0.56 mm; 95% CI: 0.43-0.70, p = 0.007). No significant differences in the uncorrected distant visual acuity, best corrected visual acuity, intraocular pressure, tear film break-up time, lipid layer thickness, and corneal endothelial cell density were found between the OK and AOK groups.
In slowing the axial elongation, 0.01% atropine alone and OK alone have similar effects, while AOK is more effective than OK alone in slowing down the axial elongation. Furthermore, the baseline degree of myopia and treatment duration may affect changes in axial elongation.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0282286</identifier><identifier>PMID: 37494360</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acuity ; Atropine ; Atropine - therapeutic use ; Axial Length, Eye ; Bias ; Biology and Life Sciences ; Care and treatment ; Cell density ; Child ; Clinical trials ; Cohort analysis ; Collaboration ; Comparative analysis ; Complications and side effects ; Cornea ; Diagnosis ; Diameters ; Effectiveness ; Elongation ; Endothelial cells ; Humans ; Intraocular pressure ; Lipids ; Medicine and Health Sciences ; Meta-analysis ; Myopia ; Myopia - drug therapy ; Orthokeratologic Procedures ; Patient outcomes ; People and Places ; Physical Sciences ; Refraction, Ocular ; Research and Analysis Methods ; Retina ; Safety ; Signal transduction ; Thickness ; Vision disorders in children ; Visual Acuity</subject><ispartof>PloS one, 2023-07, Vol.18 (7), p.e0282286-e0282286</ispartof><rights>Copyright: © 2023 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>COPYRIGHT 2023 Public Library of Science</rights><rights>2023 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 Wang et al 2023 Wang et al</rights><rights>2023 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c627t-abbc4298ce487d181a5c6d00fecbad534d8bb33792aabacceeb96fb190ba1e9a3</citedby><cites>FETCH-LOGICAL-c627t-abbc4298ce487d181a5c6d00fecbad534d8bb33792aabacceeb96fb190ba1e9a3</cites><orcidid>0000-0002-4095-7945</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370708/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370708/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37494360$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Li, Wei</contributor><creatorcontrib>Wang, Zengying</creatorcontrib><creatorcontrib>Wang, Pengfei</creatorcontrib><creatorcontrib>Jiang, Bohua</creatorcontrib><creatorcontrib>Meng, Yifei</creatorcontrib><creatorcontrib>Qie, Sufang</creatorcontrib><creatorcontrib>Yan, Zhipeng</creatorcontrib><title>The efficacy and safety of 0.01% atropine alone or combined with orthokeratology for children with myopia: A meta-analysis</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>To evaluate the efficacy and safety of 0.01% atropine alone and in combination with orthokeratology for myopia control using a meta-analysis.
PubMed, Cochrane Library, and EMBASE were searched. We included eligible randomized controlled trials (RCTs), non-RCTs, and retrospective cohort studies, published up to August 1, 2022. We calculated the weighted mean difference (WMD) and 95% confidence interval (CI) for all outcomes and plotted them in forest plots.
Fourteen studies were included; 4 and 11 in the 0.01% atropine monotherapy and atropine-orthokeratology (AOK) groups, respectively. Compared with orthokeratology (OK) alone, 0.01% atropine alone had similar effects on slowing the axial elongation (WMD: -0.00 mm; 95% CI: -0.05-0.04, p<0.31), while AOK significantly lowered axial growth. Moreover, the baseline myopic degree and duration of treatment were influential for the change in axial elongation (WMD: -0.12 mm; 95% CI: -0.17--0.07, p = 0.00001 and WMD: -0.11 mm; 95% CI: -0.15--0.108, p<0.00001, respectively). Additionally, the AOK may reduce the change rate of the spherical equivalent refraction and the accommodation amplitude (WMD: -0.13 D; 95% CI: 0.07-0.19, p<0.001 and WMD: -1.08 mm; 95% CI: -1.73--0.43, p<0.0001, respectively), and cause a slight increase in the diameter of the pupil (WMD: 0.56 mm; 95% CI: 0.43-0.70, p = 0.007). No significant differences in the uncorrected distant visual acuity, best corrected visual acuity, intraocular pressure, tear film break-up time, lipid layer thickness, and corneal endothelial cell density were found between the OK and AOK groups.
In slowing the axial elongation, 0.01% atropine alone and OK alone have similar effects, while AOK is more effective than OK alone in slowing down the axial elongation. Furthermore, the baseline degree of myopia and treatment duration may affect changes in axial elongation.</description><subject>Acuity</subject><subject>Atropine</subject><subject>Atropine - therapeutic use</subject><subject>Axial Length, Eye</subject><subject>Bias</subject><subject>Biology and Life Sciences</subject><subject>Care and treatment</subject><subject>Cell density</subject><subject>Child</subject><subject>Clinical trials</subject><subject>Cohort analysis</subject><subject>Collaboration</subject><subject>Comparative analysis</subject><subject>Complications and side effects</subject><subject>Cornea</subject><subject>Diagnosis</subject><subject>Diameters</subject><subject>Effectiveness</subject><subject>Elongation</subject><subject>Endothelial cells</subject><subject>Humans</subject><subject>Intraocular pressure</subject><subject>Lipids</subject><subject>Medicine and Health Sciences</subject><subject>Meta-analysis</subject><subject>Myopia</subject><subject>Myopia - drug therapy</subject><subject>Orthokeratologic Procedures</subject><subject>Patient outcomes</subject><subject>People and Places</subject><subject>Physical Sciences</subject><subject>Refraction, Ocular</subject><subject>Research and Analysis Methods</subject><subject>Retina</subject><subject>Safety</subject><subject>Signal transduction</subject><subject>Thickness</subject><subject>Vision disorders in children</subject><subject>Visual Acuity</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkk1v1DAQhiMEoqXwDxBYQiA4bHDsfHJBq4qPSpUqQeFqTZzxxsWJl9gBwq_HYdNqF_WAfLA1fuZ9RzMTRY8TGie8SF5f2XHowcRb22NMWclYmd-JjpOKs1XOKL-79z6KHjh3RWnGyzy_Hx3xIq1SntPj6PdliwSV0hLkRKBviAOFfiJWERrT5DkBP9it7pGACU7EDkTarg6BhvzUvg0B39pvOIC3xm4momai1aYZsN8R3RQE4A1Zkw49rCBUPTntHkb3FBiHj5b7JPry_t3l6cfV-cWHs9P1-UrmrPArqGuZsqqUmJZFk5QJZDJvKFUoa2gynjZlXXNeVAygBikR6ypXdVLRGhKsgJ9ET3e6W2OdWNrmBCtTFnqQV1kg3i7EWHfYSOz9AEZsB93BMAkLWhz-9LoVG_tDJJQXtKBlUHi5KAz2-4jOi047icZAj3b8a8ZnNq8C-uwf9PaSFmoDBoXulQ3GchYV6yIrM8YqPtvGt1DhNNhpGcaldIgfJLw6SAiMx19-A6Nz4uzzp_9nL74esi_22BbB-NZZM3pte3cIpjtQDta5AdVNlxMq5r2-7oaY91osex3SnuxP6CbpepH5HzAx9Nc</recordid><startdate>20230726</startdate><enddate>20230726</enddate><creator>Wang, Zengying</creator><creator>Wang, Pengfei</creator><creator>Jiang, Bohua</creator><creator>Meng, Yifei</creator><creator>Qie, Sufang</creator><creator>Yan, Zhipeng</creator><general>Public Library of Science</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4095-7945</orcidid></search><sort><creationdate>20230726</creationdate><title>The efficacy and safety of 0.01% atropine alone or combined with orthokeratology for children with myopia: A meta-analysis</title><author>Wang, Zengying ; Wang, Pengfei ; Jiang, Bohua ; Meng, Yifei ; Qie, Sufang ; Yan, Zhipeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c627t-abbc4298ce487d181a5c6d00fecbad534d8bb33792aabacceeb96fb190ba1e9a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acuity</topic><topic>Atropine</topic><topic>Atropine - therapeutic use</topic><topic>Axial Length, Eye</topic><topic>Bias</topic><topic>Biology and Life Sciences</topic><topic>Care and treatment</topic><topic>Cell density</topic><topic>Child</topic><topic>Clinical trials</topic><topic>Cohort analysis</topic><topic>Collaboration</topic><topic>Comparative analysis</topic><topic>Complications and side effects</topic><topic>Cornea</topic><topic>Diagnosis</topic><topic>Diameters</topic><topic>Effectiveness</topic><topic>Elongation</topic><topic>Endothelial cells</topic><topic>Humans</topic><topic>Intraocular pressure</topic><topic>Lipids</topic><topic>Medicine and Health Sciences</topic><topic>Meta-analysis</topic><topic>Myopia</topic><topic>Myopia - drug therapy</topic><topic>Orthokeratologic Procedures</topic><topic>Patient outcomes</topic><topic>People and Places</topic><topic>Physical Sciences</topic><topic>Refraction, Ocular</topic><topic>Research and Analysis Methods</topic><topic>Retina</topic><topic>Safety</topic><topic>Signal transduction</topic><topic>Thickness</topic><topic>Vision disorders in children</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Zengying</creatorcontrib><creatorcontrib>Wang, Pengfei</creatorcontrib><creatorcontrib>Jiang, Bohua</creatorcontrib><creatorcontrib>Meng, Yifei</creatorcontrib><creatorcontrib>Qie, Sufang</creatorcontrib><creatorcontrib>Yan, Zhipeng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Zengying</au><au>Wang, Pengfei</au><au>Jiang, Bohua</au><au>Meng, Yifei</au><au>Qie, Sufang</au><au>Yan, Zhipeng</au><au>Li, Wei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The efficacy and safety of 0.01% atropine alone or combined with orthokeratology for children with myopia: A meta-analysis</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2023-07-26</date><risdate>2023</risdate><volume>18</volume><issue>7</issue><spage>e0282286</spage><epage>e0282286</epage><pages>e0282286-e0282286</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>To evaluate the efficacy and safety of 0.01% atropine alone and in combination with orthokeratology for myopia control using a meta-analysis.
PubMed, Cochrane Library, and EMBASE were searched. We included eligible randomized controlled trials (RCTs), non-RCTs, and retrospective cohort studies, published up to August 1, 2022. We calculated the weighted mean difference (WMD) and 95% confidence interval (CI) for all outcomes and plotted them in forest plots.
Fourteen studies were included; 4 and 11 in the 0.01% atropine monotherapy and atropine-orthokeratology (AOK) groups, respectively. Compared with orthokeratology (OK) alone, 0.01% atropine alone had similar effects on slowing the axial elongation (WMD: -0.00 mm; 95% CI: -0.05-0.04, p<0.31), while AOK significantly lowered axial growth. Moreover, the baseline myopic degree and duration of treatment were influential for the change in axial elongation (WMD: -0.12 mm; 95% CI: -0.17--0.07, p = 0.00001 and WMD: -0.11 mm; 95% CI: -0.15--0.108, p<0.00001, respectively). Additionally, the AOK may reduce the change rate of the spherical equivalent refraction and the accommodation amplitude (WMD: -0.13 D; 95% CI: 0.07-0.19, p<0.001 and WMD: -1.08 mm; 95% CI: -1.73--0.43, p<0.0001, respectively), and cause a slight increase in the diameter of the pupil (WMD: 0.56 mm; 95% CI: 0.43-0.70, p = 0.007). No significant differences in the uncorrected distant visual acuity, best corrected visual acuity, intraocular pressure, tear film break-up time, lipid layer thickness, and corneal endothelial cell density were found between the OK and AOK groups.
In slowing the axial elongation, 0.01% atropine alone and OK alone have similar effects, while AOK is more effective than OK alone in slowing down the axial elongation. Furthermore, the baseline degree of myopia and treatment duration may affect changes in axial elongation.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>37494360</pmid><doi>10.1371/journal.pone.0282286</doi><tpages>e0282286</tpages><orcidid>https://orcid.org/0000-0002-4095-7945</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2023-07, Vol.18 (7), p.e0282286-e0282286 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2842436695 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Acuity Atropine Atropine - therapeutic use Axial Length, Eye Bias Biology and Life Sciences Care and treatment Cell density Child Clinical trials Cohort analysis Collaboration Comparative analysis Complications and side effects Cornea Diagnosis Diameters Effectiveness Elongation Endothelial cells Humans Intraocular pressure Lipids Medicine and Health Sciences Meta-analysis Myopia Myopia - drug therapy Orthokeratologic Procedures Patient outcomes People and Places Physical Sciences Refraction, Ocular Research and Analysis Methods Retina Safety Signal transduction Thickness Vision disorders in children Visual Acuity |
| title | The efficacy and safety of 0.01% atropine alone or combined with orthokeratology for children with myopia: A meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A40%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20efficacy%20and%20safety%20of%200.01%25%20atropine%20alone%20or%20combined%20with%20orthokeratology%20for%20children%20with%20myopia:%20A%20meta-analysis&rft.jtitle=PloS%20one&rft.au=Wang,%20Zengying&rft.date=2023-07-26&rft.volume=18&rft.issue=7&rft.spage=e0282286&rft.epage=e0282286&rft.pages=e0282286-e0282286&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0282286&rft_dat=%3Cgale_plos_%3EA758522938%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2842436695&rft_id=info:pmid/37494360&rft_galeid=A758522938&rfr_iscdi=true |